Earnings Summary

Immunitybio Inc.’s revenue fell -88.89% since last year same period to $0.04Mn in the Q1 2024. On a quarterly growth basis, Immunitybio Inc. has generated -71.22% fall in its revenue since last 3-months.

Immunitybio Inc.’s net profit jumped 11.28% since last year same period to $-134.11Mn in the Q1 2024. On a quarterly growth basis, Immunitybio Inc. has generated 42.54% jump in its net profits since last 3-months.

Immunitybio Inc.’s net profit margin fell -698.47% since last year same period to -335272.5% in the Q1 2024. On a quarterly growth basis, Immunitybio Inc. has generated -99.68% fall in its net profit margins since last 3-months.

Immunitybio Inc.’s earning per share (EPS) estimates for the current year stand at -0.16.

Immunitybio Inc.’s earning per share (EPS) jumped 25.93% since last year same period to -0.2 in the Q1 2024. This indicates that the Immunitybio Inc. has generated 25.93% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Immunitybio Inc.’s return on assets (ROA) stands at -0.58.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Immunitybio Inc.’s return on equity (ROE) stands at 0.